This program was cosupported by educational grants from AbbVie Inc.; Intra-Cellular Therapies; Neurocrine; and Sunovion.
This activity is supported by educational grants from AbbVie Inc.; Intra-Cellular Therapies; and Sunovion.
NPs and PAs
Upon completion of this activity, participants should be able to:
Accurately diagnose depressive episodes in individuals with bipolar disorder, recognize clinical subcharacteristics that may influence treatment outcomes
Recognize the limited role for use of antidepressants in bipolar depression and risk for lack of efficacy versus treatment-emergent affective switch
Understand the antidepressant properties of mood stabilizers, second generation antipsychotics, and emerging novel therapeutics for depression in bipolar disorder
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Asbach has disclosed that he has received consulting fees from Biogen and Neurocrine Biosciences; and has received fees for non-CME/CE services from AbbVie, Avanir, Johnson & Johnson, Otsuka, and Neurocrine Biosciences.
Dr Cunningham has no relevant financial relationships to disclose.
Dr Suppes has disclosed that she has received consulting fees from Allergan, Impel Neuropharma, Intra-Cellular Therapies, Merck, and Sunovion; has received fees for non-CME/CE services from Servier (Australia) and Sunovion; and has received funds for research support from and Merck.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Mr Asbach as noted above.
Participants wishing to earn CE/CME credit must:
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 75%.
The estimated time to complete this activity is 1.00 hour.
Release date: January 24, 2022
Expiration date: January 23, 2023
Interactive video lecture
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Patricia Cunningham, DNSc, PMHNP, FNP, Clinical Neuroscience Solutions, Memphis, Tennessee
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until January 23, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Michael Asbach, PA-C, Psych-CAQ, Daemen College, Amherst, New York
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program has been made available online.